Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H28N2O |
Molecular Weight | 288.4284 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCN1CCCCC1C(=Nc2c(C)cccc2C)O
InChI
InChIKey=LEBVLXFERQHONN-UHFFFAOYSA-N
InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
Molecular Formula | C18H28N2O |
Molecular Weight | 288.4284 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11895133
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11895133
Bupivacaine is a widely used local anesthetic agent. Bupivacaine is often administered by spinal injection prior to total hip arthroplasty. It is also commonly injected into surgical wound sites to reduce pain for up to 20 hours after surgery. In comparison to other local anesthetics it has a long duration of action. It is also the most toxic to the heart when administered in large doses. Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Bupivacaine binds to the intracellular portion of sodium channels and blocks sodium influx into nerve cells, which prevents depolarization. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. The analgesic effects of bupivicaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia. Bupivacaine sometimes used in combination with epinephrine to prevent systemic absorption and extend the duration of action.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12761351 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EXPAREL Approved UseBupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See WARNINGS .) Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of Bupivacaine Hydrochloride in these patients. Bupivacaine Hydrochloride is not recommended for intravenous regional anesthesia (Bier Block). (See WARNINGS .) The routes of administration and indicated Bupivacaine Hydrochloride concentrations are: • local infiltration 0.25% • peripheral nerve block 0.25% and 0.5% • retrobulbar block 0.75% • sympathetic block 0.25% • lumbar epidural 0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) • caudal 0.25% and 0.5% • epidural test dose 0.5% with epinephrine 1:200,000 • dental blocks 0.5% with epinephrine 1:200,000 (See DOSAGE AND ADMINISTRATION for additional information.) Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of Bupivacaine Hydrochloride. Launch Date1.31976004E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
952 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
810 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3868 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4096 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3344993/ |
2.5 mg/kg single, caudal dose: 2.5 mg/kg route of administration: Caudal experiment type: SINGLE co-administered: |
BUPIVACAINE blood | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3344993/ |
2.5 mg/kg single, caudal dose: 2.5 mg/kg route of administration: Caudal experiment type: SINGLE co-administered: |
BUPIVACAINE blood | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day single, intramuscular Studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, 11 months n = 1 Health Status: healthy Age Group: 11 months Population Size: 1 Sources: |
Other AEs: Ventricular tachycardia... |
103 mg 1 times / day single, intravenous MTD Dose: 103 mg, 1 times / day Route: intravenous Route: single Dose: 103 mg, 1 times / day Sources: |
healthy, mean age 28 years n = 12 Health Status: healthy Age Group: mean age 28 years Sex: M Population Size: 12 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ventricular tachycardia | 40 mg 1 times / day single, intramuscular Studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, 11 months n = 1 Health Status: healthy Age Group: 11 months Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Etidocaine, bupivacaine, and lidocaine seizure thresholds in monkeys. | 1975 Apr |
|
Side-effects of epidural infusions of opioid bupivacaine mixtures. | 1998 Dec |
|
Combined spinal epidural for labour analgesia--duration, efficacy and side effects of adding sufentanil or fentanyl to bupivacaine intrathecally vs plain bupivacaine. | 1999 Oct |
|
A multicentre trial of ropivacaine 7.5 mg x ml(-1) vs bupivacaine 5 mg x ml(-1) for supra clavicular brachial plexus anesthesia. | 1999 Oct |
|
A direct search procedure to optimize combinations of epidural bupivacaine, fentanyl, and clonidine for postoperative analgesia. | 2000 Feb |
|
Bupivacaine inhibits baroreflex control of heart rate in conscious rats. | 2000 Jan |
|
Minidose bupivacaine-fentanyl spinal anesthesia for surgical repair of hip fracture in the aged. | 2000 Jan |
|
Phantom pain and regional anaesthesia. | 2000 Jun |
|
The dose-response of intrathecal sufentanil added to bupivacaine for labor analgesia. | 2000 Jun |
|
Lumbar sympathetic block for sympathetically maintained pain: changes in cutaneous temperatures and pain perception. | 2000 Jun |
|
Mental status change and aphasia after labor analgesia with intrathecal sufentanil/bupivacaine. | 2000 May |
|
Advantages of intrathecal nalbuphine, compared with intrathecal morphine, after cesarean delivery: an evaluation of postoperative analgesia and adverse effects. | 2000 Sep |
|
Patient-controlled spinal analgesia for labour and caesarean delivery. | 2001 Feb |
|
Pediatric caudal block with mepivacaine, bupivacaine or a mixture of both drugs: requirement for postoperative analgesia and plasma concentration of local anesthetics. | 2001 Feb |
|
[Bupivacaine in continuous epidural infusion using a portable mechanical devise for postoperative analgesia after surgery for hernia of the lumbar disk]. | 2001 Feb |
|
[Anesthetic management for the correction of pectus excavatum using pectus bar under video-assistance]. | 2001 Feb |
|
Can anesthesiologic strategies for caesarean section influence newborn jaundice? A retrospective and prospective study. | 2001 Feb |
|
Subarachnoid sufentanil for early postoperative pain management in orthopedic patients: a placebo-controlled, double-blind study using spinal microcatheters. | 2001 Feb |
|
Epidural fentanyl markedly improves thoracic epidural analgesia in a low-dose infusion of bupivacaine, adrenaline and fentanyl. A randomized, double-blind crossover study with and without fentanyl. | 2001 Feb |
|
Irreversible block of human heart (hH1) sodium channels by the plant alkaloid lappaconitine. | 2001 Feb |
|
Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep. | 2001 Feb |
|
Is comparative cardiotoxicity of S(-) and R(+) bupivacaine related to enantiomer-selective inhibition of L-type Ca(2+) channels? | 2001 Feb |
|
Extended femoral nerve sheath block after total hip arthroplasty: continuous versus patient-controlled techniques. | 2001 Feb |
|
Levobupivacaine for epidural analgesia in labor: the sparing effect of epidural fentanyl. | 2001 Feb |
|
Transient neurologic symptoms after spinal anesthesia with lidocaine in obstetric patients. | 2001 Feb |
|
Does pregnancy protect against intrathecal lidocaine-induced transient neurologic symptoms? | 2001 Feb |
|
Postoperative sleep disturbance: influences of opioids and pain in humans. | 2001 Feb 1 |
|
A randomised controlled trial of epidural compared with non-epidural analgesia in labour. | 2001 Jan |
|
Epidural naloxone reduces intestinal hypomotility but not analgesia of epidural morphine. | 2001 Jan |
|
[Low concentration/high volume is more effective than high concentration/low volume for postoperative continuous epidural analgesia with the combination of bupivacaine and fentanyl]. | 2001 Jan |
|
Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). | 2001 Jan |
|
Digitally assisted acromioplasty: the effect of interscalene block on this new surgical technique. | 2001 Jan |
|
Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. | 2001 Jan |
|
Neurologic sequelae after caesarean section. | 2001 Jan |
|
Anesthetic management of a parturient with superior vena cava obstruction for cesarean section. | 2001 Jan |
|
Clonidine combined with a long acting local anesthetic does not prolong postoperative analgesia after brachial plexus block but does induce hemodynamic changes. | 2001 Jan |
|
Bupivacaine wound instillation via an electronic patient-controlled analgesia device and a double-catheter system does not decrease postoperative pain or opioid requirements after major abdominal surgery. | 2001 Jan |
|
Dexamethasone facilitates discharge after outpatient anorectal surgery. | 2001 Jan |
|
Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs. | 2001 Jan |
|
Morphine with or without a local anaesthetic for postoperative intrathecal pain treatment after selective dorsal rhizotomy in children. | 2001 Jan |
|
Randomized clinical trial of local bupivacaine perfusion versus parenteral morphine infusion for pain relief after laparotomy. | 2001 Mar |
|
Functional characterisation of human TASK-3, an acid-sensitive two-pore domain potassium channel. | 2001 Mar |
|
Corneal sensation after topical anesthesia. | 2001 Mar |
|
Epidural analgesia in the dog and cat. | 2001 Mar |
|
Discomfort with fine-needle aspiration cytology of the breast. | 2001 Mar 10 |
|
Postoperative narcotic requirement after microscopic lumbar discectomy is not affected by intraoperative ketorolac or bupivacaine. | 2001 Mar 15 |
|
Characterization of TASK-4, a novel member of the pH-sensitive, two-pore domain potassium channel family. | 2001 Mar 9 |
|
Low-dose spinal anesthesia for cesarean delivery: Have we gone too far? | 2001 Mar-Apr |
|
Endoscopic technique with ultrasound imaging for neurolytic celiac plexus block. | 2001 Mar-Apr |
|
Assessment of wound infiltration with bupivacaine in women undergoing day-case gynecological laparoscopy. | 2001 Mar-Apr |
Sample Use Guides
single-dose administration only. maximum dosage of EXPAREL ((Bupivacaine Liposome Injectable Suspension) should not exceed 266 mg (20 mL, 1.3% of undiluted drug).
Route of Administration:
Intravascular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27195613
Bupivacaine increased the phosphorylation of GSK-3β(Tyr216) in ovarian carcinoma (SKOV-3) but without measurable effect in prostate carcinoma (PC3). GSK-3β inhibition and siRNA gene knockdown decreased bupivacaine induced cell death in SKOV-3 but not in PC3.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:35:10 UTC 2021
by
admin
on
Fri Jun 25 21:35:10 UTC 2021
|
Record UNII |
Y8335394RO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007681
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
NDF-RT |
N0000175976
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
FDA ORPHAN DRUG |
237207
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
WHO-VATC |
QN01BB01
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
WHO-VATC |
QN01BB51
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
NDF-RT |
N0000175682
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
NCI_THESAURUS |
C245
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
WHO-ATC |
N01BB51
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
WHO-ATC |
N01BB01
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
1.2
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
218-553-3
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
ALTERNATIVE | |||
|
2180-92-9
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
SUPERSEDED | |||
|
2474
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
M2769
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | Merck Index | ||
|
1815
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
Bupivacaine
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
253-911-2
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
C62011
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
38396-39-3
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
Y8335394RO
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
D002045
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
CHEMBL1098
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
7790
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
DB00297
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
2397
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
BUPIVACAINE
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
38396-39-3
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
2279
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
432
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY | |||
|
SUB05983MIG
Created by
admin on Fri Jun 25 21:35:11 UTC 2021 , Edited by admin on Fri Jun 25 21:35:11 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
EXCRETED UNCHANGED |
URINE
|
||
|
SUB_CONCEPT->SUBSTANCE | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
After injection of Bupivacaine Hydrochloride for caudal, epidural, or peripheral nerve block in man |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||